Table 6.
Summary of outcomes resulting from introducing non-invasive liver fibrosis tests in primary care (per 1000 NAFLD patients over 1 years)
| Scenario 1 Standard Care |
Scenario 2 FIB 4 +/− ELF |
Scenario 3 FIB 4 +/− TE |
Scenario 4 ELF |
Scenario 5 TE |
|
|---|---|---|---|---|---|
| Total Referrals avoided (vs. SOC) | – | 245 | 234 | 198 | 150 |
| Cases F3/F4 detected | 26.3 | 56.1 | 57.1 | 60.0 | 62.2 |
| Cases Cirrhosis detected | 5.3 | 11.0 | 11.2 | 11.8 | 12.3 |
| Cases Cirrhosis missed | 11.3 | 5.5 | 5.3 | 4.7 | 4.2 |
| Cost saving (vs. SOC) | – | - £169,408 | - £151,816 | - £101,268 | - £26,889 |
| Cost per ≥ F3 detected | £25,543 | £8932 | £9083 | £9487 | £10,351 |